ERIN SMITH: Open Payments
NPI 1205473253 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,040 in 149 payments from 29 companies in 2025. Trend: 2023 $2,500 · 2024 $3,772 · 2025 $3,040
Food & beverage: $3,040
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $846 |
| PFIZER INC. | 29 | $384 |
| Novartis Pharmaceuticals Corporation | 19 | $382 |
| UCB, Inc. | 9 | $227 |
| Lundbeck LLC | 6 | $113 |
| SK Life Science, Inc. | 4 | $102 |
| ANI Pharmaceuticals, Inc. | 3 | $76 |
| Cala Health, Inc. | 2 | $73 |
| Alexion Pharmaceuticals, Inc. | 3 | $71 |
| AstraZeneca Pharmaceuticals LP | 4 | $70 |
Products named: QULIPTA, KESIMPTA, BOTOX, NURTEC ODT, UBRELVY, PANZYGA, Fintepla, REXULTI.
Industry payments across MS — which companies pay providers there.
